Zhijian Xiao
The 6th Department of Clinical Hematology
Institute of Hematology and Blood Diseases Hospital
Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin 300020
China
Name/email consistency: high
- Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study. Xiao, Z., Xu, Z., Zhang, Y., Qin, T., Zhang, H., Fang, L. Leuk. Res. (2011)
- Glutathione S-transferases (GSTT1 and GSTM1) genes polymorphisms and the treatment response and prognosis in Chinese patients with de novo acute myeloid leukemia. Xiao, Z., Yang, L., Xu, Z., Zhang, Y., Liu, L., Nie, L., Li, L., Wang, J., Hao, Y. Leuk. Res. (2008)
- The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia. Xiao, Z., Xue, H., Li, R., Zhang, L., Yu, M., Hao, Y. Am. J. Hematol. (2008)
- Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Xiao, Z., Wang, Y., Lu, L., Li, Z., Peng, Z., Han, Z., Hao, Y. Leuk. Res. (2006)
- MEL1S, not MEL1, is overexpressed in myelodysplastic syndromes patients with t(1;3)(p36;q21). Xiao, Z., Zhang, M., Liu, X., Zhang, Y., Yang, L., Hao, Y. Leuk. Res. (2006)
- Isochromosome 17q in patients with myelodysplastic syndromes: six new cases. Xiao, Z., Liu, S., Yu, M., Xu, Z., Hao, Y. Haematologica (2003)
- Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Xiao, Z., Hao, Y., Liu, B., Qian, L. Leuk. Lymphoma (2002)









